The deal, announced last week, gives Prothena $60 million in upfront cash and potentially up to $1.17 billion tied to achieving development, commercialization and net sales-based milestones, starting with $40 million if the anti-amyloid immunotherapy advances to Phase II . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge